Clinical Trial Update: A Trial Evaluating TG4050 in Ovarian Carcinoma. [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating TG4050 for ovarian cancer (including fallopian tube and peritoneal cancers) has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• TG4050

Snippet

Sponsor: Transgene | Conditions: Ovarian Carcinoma, Fallopian Tube Cancer | Phase 1 | Status: COMPLETED | Results posted: 2025-11-14